India's Zydus Lifesciences gains after U.S. FDA inspection ends with nil observations
BUZZ-India's Zydus Lifesciences gains after U.S. FDA inspection ends with nil observations ** Shares of India's Zydus Lifesciences ZYDU.NS rise as much as 2.1% to 1,228.60 rupees, stock last up 1.8%
** Stock set for ninth session of gains
** Drugmaker says U.S. FDA inspection of its pharmacovigilance and post-marketing surveillance system at its New Jersey office concluded with nil observations
** Adds inspection was conducted from September 22, 2026 to September 25, 2026
** Stock rated "buy" on average by 29 analysts; median PT is 1,205 rupees - LSEG compiled data
** Stock up 34% YTD
(Reporting by Payel Das in Bengaluru)
Recent news on Zydus Lifesciences
See all newsIndia's Zydus Lifesciences posts lower profit as expenses outpace revenue growth
Brief: Zydus Lifesciences Q2 Consol Net Profit 9.26 Billion Rupees
Brief: Zydus Lifesciences Says Zylidac Bio And Prolific Machines Partner
Brief: Zydus Lifesciences Receives U.S. FDA Approval For Estradiol And Levonorgestrel Transdermal System
Brief: Zydus Lifesciences Says Zydus Sunshine Lifesciences Signs Agreement To Establish A Pharmaceutical Manufacturing Facility In Sri Lanka